Navigation Links
Genomas Awarded $1.2 Million NIH SBIR Grant to Develop DNA-Guided System for Management of Statin Therapy

HARTFORD, Conn., March 19 /PRNewswire-FirstCall/ -- Genomas(R), a biomedical company advancing DNA-guided medicine and personalized healthcare, today announced the award of a Fast-Track Phase I-II Small Business Innovation Research (SBIR) Grant totaling $1.2 million. The grant, entitled "DNA Diagnostic System for Statin Safety and Efficacy," was awarded by the National Institute of General Medical Sciences (NIGMS).

Statins are the most prescribed drugs in the world. Drugs in this class include atorvastatin (Lipitor(R)), rosuvastatin (Crestor(R)), and simvastatin (Zocor(R) and generic formulations). Statin-induced neuro-myopathy (SINM) is the main clinically relevant safety risk of these drugs. In medical practice, SINM presents as a constellation of nerve and muscle side effects. Clinical symptoms of SINM include muscle aches (myalgia), cramps, weakness, and muscle injury (myositis, monitored in serum by elevation of certain enzymes). Statin usage is ultimately limited by these side effects which are disabling to 10% of patients, require alteration of therapy, burden healthcare with management costs, and reduce compliance.

Under the SBIR program, Genomas will integrate the clinical expertise of its strategic partner, Hartford Hospital, with the company's proprietary physiogenomics technology to develop DNA-guided clinical management systems that predict and compare an individual's risk of SINM from statin medications. PhyzioType(TM) Clinical Management Systems are composed of an ensemble of inherited DNA markers genotyped by arrays and interpreted by a biomathematical algorithm in order to convey to physicians predicted comparisons of side effect risk among drugs for the individual patient.

In announcing the award, Gualberto Ruano, M.D., Ph.D., President and CEO of Genomas commented: "By interfacing complex patient reactions to statin drugs with physiogenomics, we can translate the variability observed in medical practice into clinical decision support for DNA-guided medicine. Our revolutionary SINM PhyzioType(TM) System enables the diagnosis and drug-specific prediction of statin neuromuscular side effects addressing a high impact medical need in cardiovascular medicine and will be significantly advanced with this major SBIR award."

The research leading to this award has been published in the renowned journal Muscle & Nerve in September 2007. Researchers at the Division of Cardiology of Hartford Hospital and at the Department of Laboratory Medicine, University of California San Francisco, were co-authors of the publication and are co-investigators in the grant, which also includes the Rogosin Institute.

To date, Genomas has secured $3.1 million of NIH SBIR funding for PhyzioType(TM) product development. These programs have been anchored by the novel partnership with Hartford Hospital for translating DNA-guided medicine into clinical practice.


Genomas(R) Inc. is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs in cardiovascular and psychiatric medicine. PhyzioType(TM) Systems provide physicians with the unprecedented capability to select for each patient the safest drug treatment. Genomas is located in Hartford, CT on the campus of Hartford Hospital. For more information please access

SOURCE Genomas, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. Mirus Bio Awarded Grants & Contracts of Over $5 Million
3. ICx Awarded $1.5 M Contract by Department of Homeland Security for Development of Next Generation Bio Aerosol Systems
4. ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS
5. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
8. Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics
9. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
10. Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats
11. BIO-key(R) Awarded Contract to Deploy Incident Reporting System for Littleton, CO Police Department
Post Your Comments:
(Date:10/13/2015)... and SAN DIEGO , ... Mast Therapeutics, Inc. have agreed to collaborate in the ... poloxamer 188 NF, marketed by BASF under the Kolliphor ... a variety of pharmaceutical and biological applications, such as ... is the starting material for Mast,s lead product candidate. ...
(Date:10/13/2015)... 13, 2015  According to Kalorama Information, the ... $102 billion by the end of 2015. Clinical ... industry, as it is estimated that approximately 80% ... tests. In addition to diagnosing patients, clinical lab ... progression, monitor drug treatment and conditions, and determine ...
(Date:10/13/2015)... ... October 13, 2015 , ... Clinovo recently appointed Jeff ... the company’s fast growing clinical data solutions business. , Jeff Parr has spent the ... all sizes, including Avery Dennison, Thermo Fisher, and Ab Sciex to name a few. ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... opportunities for school age children in the areas of Science, Technology, Engineering and ... of the national economy, and the program aims to increase the number of ...
Breaking Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court ... issued another key ruling in favor of Crossmatch ... Korean fingerprint scanner company Suprema and its U.S. partner ... 1930, a trade provision that declares it unlawful to ... by infringing two of Crossmatch,s patents, the 5,900,993 patent ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced that Lenovo has selected Synaptics , ... FS4202, for its latest smartphone, the Vibe P1. The ... to unlock the device and provide swift access to ... The feature-rich Natural ID FS4202 sensor solution utilizes AES256-bit ...
Breaking Biology News(10 mins):